Background: Human serum paraoxonase (PON1) residing on HDL can prevent the oxidation of low densitylipoprotein (LDL), the initiating factor in atherosclerosis. Statins are commonly used to treat dyslipidemia,aknown risk factor for coronary artery disease (CAD).The aim of the studyis to evaluate the alterations in theconcentrationof PON1 along with that of other parameters of lipid profile in patients of CAD before and after 3 months of statin therapy.Materials and Methods: The study included 30 new patients who were put on statin therapy following thediagnosis of acute coronary syndrome. The activity of PON1 (units-IU/L) and the concentration of lipid profileparameters (units-mg/dl) were estimated before starting statin therapy and again after three months. Patients with co-morbidities like diabetes, kidney disease, liver disease and other cardiac diseases of infectious aetiology were excluded.Results and Analysis: As expected, both PON1 and HDL have increased after 3 months. There was a statistically significant increase in both PON1 (p<0.05)and HDL (p<0.001) and a decrease (p <0.05, also statistically significant)in LDL after 3 months of statin therapy.Conclusion: This knowledge may be exploited in the follow up CAD patients. The increase in PONI and thesimilar increase in HDL after 3 months of statin therapy may be exploited in the follow-up of cardiac patients.